SCHEMBL7061528

SCHEMBL7061528

Cn1c2c(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)[S+]([O-])C(C(=O)O)C(=O)N2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.34
PTGS1 P23219 2/20 0.33
PTGS2 P35354 2/20 0.33
GAA P10253 1/20 0.33
BRD4 O60885 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
GPR18 Q14330 1/20 0.31
P2RX3 P56373 1/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2B Q13224 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130471 0.86 ALDH1A1 (0.37) ALDH1A1TSHRMEN1CYP3A4CYP2C9
SCHEMBL7127235 0.86 ADORA2A (0.33) ALDH1A1L3MBTL1TSHRMEN1CYP3A4
SCHEMBL7059744 0.86 GAA (0.43) ALDH1A1L3MBTL1MEN1CYP3A4CYP2C9
SCHEMBL6678209 0.77 ALDH1A1 (0.38) ALDH1A1L3MBTL1TSHRMEN1CYP3A4
SCHEMBL7063104 0.77 ALDH1A1 (0.37) ALDH1A1L3MBTL1TSHRMEN1CYP3A4
SCHEMBL7126064 0.77 L3MBTL1 (0.40) ALDH1A1L3MBTL1TSHRMEN1CYP3A4
SCHEMBL7120575 0.77 ALDH1A1 (0.47) ALDH1A1L3MBTL1TSHRMEN1CYP3A4
SCHEMBL7116516 0.72 ALDH1A1 (0.38) ALDH1A1TSHRMEN1CYP3A4CYP2C9
SCHEMBL7118338 0.72 KDM4E (0.37) ALDH1A1L3MBTL1LMNAGAAKDM4E
SCHEMBL7115712 0.71 MEN1 (0.40) ALDH1A1L3MBTL1MEN1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 ALDH1A1 812/4885L3MBTL1 2277/4885TSHR 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.